期刊
HEMASPHERE
卷 4, 期 4, 页码 -出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HS9.0000000000000432
关键词
-
类别
资金
- Abbvie
- Gilead
- Janssen
- Cellestia
- Mustang Bio
- Celgene
- Bristol Myers Squibb
- Pharmacyclics
- Genentech
- TG Therapeutics
- Beigene
- Astra Zeneca
- Sunesis
- Acerta Pharma
- Merck
- Loxo
- Sun
- Verastem
- Acerta
- Roche
- Mundipharma
- Johnson Johnson
- Regeneron
- Portola
- DTRM
- Novartis
Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and background risk factors that apply to the general population for severe COVID-19. On these bases, patients with CLL may experience COVID-19 morbidity and mortality. Recurrent seasonal epidemics of SARS-CoV-2 are expected, and doctors taking care of patients with CLL must be prepared for the possibility of substantial resurgences of infection and adapt their approach to CLL management accordingly. In this Guideline Article, we aim at providing clinicians with a literature-informed expert opinion on the management of patients with CLL during SARS-CoV-2 epidemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据